Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

Jiangxue Hou; Yufu Li; Quande Lin

doi:10.1186/s40164-023-00436-9

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

Exp Hematol Oncol. 2023 Aug 26;12(1):74. doi: 10.1186/s40164-023-00436-9.

Authors

Jiangxue Hou¹, Yufu Li¹, Quande Lin²

Affiliations

¹ The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
² The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China. zlyylinquande1577@zzu.edu.cn.

Abstract

Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells.

Keywords: Bispecific antibody; CAR T; Clinical trial; Multiple myeloma.

Publication types

Letter